P Kurtzhals
Overview
Explore the profile of P Kurtzhals including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
467
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen B, Kurtzhals P, Jensen A, Dejgaard A, Russell-Jones D
Diabetologia
. 2011 Jun;
54(9):2226-31.
PMID: 21633908
The molecular safety of insulin analogues has received a great deal of attention over the last year. In particular, attention has been directed to the mitogenic properties of insulin analogues...
2.
Sorensen A, Stidsen C, Ribel U, Nishimura E, Sturis J, Jonassen I, et al.
Diabetes Obes Metab
. 2010 Jul;
12(8):665-73.
PMID: 20590743
Aim: To compare the properties of insulin detemir with human insulin or insulin aspart in various in vitro and in vivo experiments, thereby highlighting the importance of performing dose-response studies...
3.
Kurtzhals P
Diabetes Metab
. 2006 Jan;
31(4 Pt 2):4S25-4S33.
PMID: 16389895
The development of insulin analogues over the last two decades have aimed at optimising the pharmacokinetic profile of subcutaneously injected insulin for therapeutic use in diabetes mellitus. Rapid acting analogues...
4.
Gammeltoft S, Hansen B, Dideriksen L, Lindholm A, Schaffer L, Trub T, et al.
Expert Opin Investig Drugs
. 2005 Jul;
8(9):1431-42.
PMID: 15992160
In order to improve therapy and increase the quality of life for diabetic patients, it has been of significant interest to develop rapid-acting insulin preparations that mimic the physiological meal-time...
5.
Kurtzhals P
Int J Obes Relat Metab Disord
. 2004 Aug;
28 Suppl 2:S23-8.
PMID: 15306834
The suboptimal nature of the absorption profiles of human insulin formulations following subcutaneous administration has prompted the development of insulin analogues better suited for therapeutic use in diabetes mellitus. A...
6.
Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al.
Diabetes
. 2000 Jun;
49(6):999-1005.
PMID: 10866053
In recent years, analogs of human insulin have been engineered with the aim of improving therapy for people with diabetes. To ensure that the safety profile of the human hormone...
7.
Kjeldsen T, Pettersson A, Drube L, Kurtzhals P, Jonassen I, Havelund S, et al.
Protein Expr Purif
. 1998 Jul;
13(2):163-9.
PMID: 9675058
Albumin is organized in three homologous domains formed by double loops stabilized by disulfide bonds. Utilizing a secretory expression system based on a synthetic secretory prepro-leader, the three human serum...
8.
Kurtzhals P, Havelund S, Jonassen I, Markussen J
J Pharm Sci
. 1998 Jan;
86(12):1365-8.
PMID: 9423147
NN304 (LysB29-tetradecanoyl, des(B30)-insulin) is a new soluble, long-acting insulin analogue that is tightly bound to human serum albumin differentiating it from human insulin. In the present study, we investigate the...
9.
Lauria M, Qureshi F, Jacques S, Kurtzhals P, Ostrea E, Gonik B, et al.
Fetal Diagn Ther
. 1997 Jul;
12(4):248-51.
PMID: 9354887
Objective: Meconium drug testing of liveborn infants is highly sensitive (87%) and specific (100%). Accurate knowledge of drug use in mothers of stillborns would be beneficial. We determined the feasibility...
10.
Markussen J, Havelund S, Kurtzhals P, Andersen A, Halstrom J, Hasselager E, et al.
Diabetologia
. 1996 Mar;
39(3):281-8.
PMID: 8721773
We have synthesized insulins acylated by fatty acids in the epsilon-amino group of LysB29. Soluble preparations can be made in the usual concentration of 600 nmol/ml (100 IU/ml) at neutral...